New survival standards for advanced melanoma
British Journal of Cancer, Published online: 17 February 2020; doi:10.1038/s41416-020-0738-5The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing the role of this combination in practice today.
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Lavinia Spain James Larkin Samra Turajlic Source Type: research
More News: Cancer | Cancer & Oncology | Melanoma | Skin Cancer | Spain Health | Study | Toxicology | UK Health | Yervoy